ONT-380: Phase Ib started

Oncothyreon began an open-label, dose-escalation, U.S. Phase Ib trial to evaluate oral ONT-380 twice daily in combination with IV Kadcyla ado-trastuzumab emtansine given every 21 days in 21-day cycles in up to 48 patients previously treated with Herceptin trastuzumab and a taxane. The trial includes an expansion arm at the MTD and/or recommended Phase II dose of ONT-380. Patients with treated stable CNS metastases will be eligible for the dose-escalation portion of the trial, while up to 15 patients with asymptomatic untreated CNS metastases may be included in an additional expansion arm. ...